Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 57 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

36 recruiting

Enrollment Performance

Analytics

Phase 1

55(96.5%)

Early Phase 1

1(1.8%)

Phase 2

1(1.8%)

57Total

Phase 1(55)

Early Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (57)

Showing 20 of 57 trials

NCT05396300Phase 1Recruiting

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Role: collaborator

NCT07456371Phase 1Recruiting

PIC1 Injection Therapy for Relapsed/Refractory B-NHL

Role: lead

NCT07403097Phase 1Recruiting

Study of CD19 CAR-T Therapy for Refractory SLE

Role: lead

NCT06222853Phase 1Active Not Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Role: collaborator

NCT07318259Phase 1Recruiting

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Role: lead

NCT06821048Phase 1Recruiting

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Role: collaborator

NCT07331467Phase 1Recruiting

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Role: lead

NCT06892145Phase 1Recruiting

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Role: lead

NCT07250386Phase 1Recruiting

A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors

Role: collaborator

NCT07247396Phase 1Recruiting

CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases

Role: collaborator

NCT07239323Phase 1Recruiting

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Role: lead

NCT07179692Phase 1Recruiting

CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

Role: lead

NCT07181720Phase 1Recruiting

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Role: lead

NCT07184450Phase 1Recruiting

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Role: lead

NCT06945523Phase 1Recruiting

Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

Role: lead

NCT05518253Phase 1Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Role: collaborator

NCT06992583Phase 1Recruiting

Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer

Role: lead

NCT06934447Phase 1Recruiting

Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

Role: collaborator

NCT06909474Phase 1Recruiting

Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

Role: lead

NCT06903117Phase 1Recruiting

Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma

Role: lead